CHEK1 and cancer: SRA737 (formerly known as CCT245737), an orally novel ATP docking site CHK1 inhibitor, is currently under clinical trials as a monotherapy or in combination with chemotherapeutic agents, in particular low-dose gemcitabine, in different cancers [22,23], which can result in remarkable increases in the sensitivity of cancer cells to diverse anticancer drugs.